Abstract 840P
Background
This study aimed to obtain a deeper understanding of the molecular mechanisms underlying extranodal NK/T-cell lymphoma, nasal type (ENKTCL) by conducting Next-Generation Sequencing (NGS) of patients with ENKTCL.
Methods
This study included patients with ENKTCL who had complete tissue NGS results from two prior prospective studies. Group 1 comprised early-stage patients, while advanced-stage or relapsed patients were classified into Group 2. R language was used to visualize the mutation data.
Results
40 out of 98 patients with ENKTCL from two prospective clinical trials were included. Group 1 comprised 67.5% (n=27) of the patients, while group 2 accounted for 32.5% (n=13). Mutations in KLRC2 (29.6%), CIITA (25.9%), KLRC1 (25.9%), ITK (18.5%) were exclusively observed in group 1, with KLRC2 mutations occurring significantly more frequently in group 1 than group 2 (P = 0.037). KMT2D and TP53 exhibited the highest mutation rates and displayed different amino acid alterations in the two groups. The top KEGG pathway enriched by mutated genes was non-small cell lung cancer in group 1, and hepatitis B pathway in group 2. Patients with JAK3 wild-type exhibited remarkably improved PFS and OS rates than those with JAK3 mutations (P = 0.003, P = 0.033). Improved OS was also observed in patients with BCOR wild-type, although no significantly difference was found in PFS (P = 0.049, P = 0.172). Patients with PD-L1-positive expression had a significantly longer OS compared to those with PD-L1-negative expression (P = 0.037). Patients with PD-L1 expression < 50% were more likely to have BCOR mutations (41.7% vs. 0%, P = 0.012) and JAK3 gene mutations (33.3% vs. 0%, P = 0.033) than those with PD-L1 expression ≥ 50%.
Conclusions
The present study has, for the first time, explored disparities in mutation rates, mutation sites, and associated pathways among patients with early-stage versus advanced-stage/relapsed ENKTCL. JAK3 mutations, BCOR mutations, and PD-L1-negative expression were associated with poor prognosis of ENKTCL. Patients with PD-L1 expression < 50% were more likely to have BCOR mutations and JAK3 mutations than those with PD-L1 expression ≥50%.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18